EDEN PRAIRIE, Minn.,
July 7, 2021 /PRNewswire/
-- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC;
NeuroOne or the Company), a medical technology company focused on
improving surgical care options and outcomes for patients suffering
from neurological disorders, announces today that the company will
present at Access to Giving Virtual Conference.
Registration Details
Date: Thursday, July 15, 2021
Time: 2 p.m. ET
Link:
https://access-to-giving.events.issuerdirect.com/signup
To learn more about the event or to schedule a one-on-one
meeting with NeuroOne's management, please visit
https://www.accesstogiving.com/ or email
james@haydenir.com.
About Access to Giving Virtual Conference
Access to Giving is a first-of-its-kind virtual investor
conference where companies from microcap all the way up to megacap
will have the opportunity to present their story and conduct 1x1
meetings with qualified investors, for charity. Investors will make
donations to purchase a block of meetings to meet with
companies.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information, visit https://www.n1mtc.com.
The Company previously announced it had successfully met the
first performance milestone in the distribution and development
agreement signed with Zimmer Biomet on July
20, 2020. In addition to acquiring exclusive global
distribution rights to NeuroOne's Evo™ (Evo) patented electrode
technology, the partnership also offered the potential for NeuroOne
to earn back-end milestone payments if certain events were met
within a specified time frame.
NeuroOne received FDA clearance for its Evo cortical technology
in November 2019.
In partnership with Mayo Clinic, Wisconsin Alumni Research
Foundation (WARF) and other prominent academic medical centers, the
Company began developing its cortical electrode technology in 2015.
The Company initially focused its efforts on the epilepsy and
intraoperative tumor monitoring markets. NeuroOne intends to
continue to develop the technology for use in therapeutic
applications for Parkinson's disease, epilepsy and pain management
due to failed back surgery procedures.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-at-access-to-giving-virtual-conference-on-july-15-2021-at-2-pm-et-301326578.html
SOURCE NeuroOne Medical Technologies Corporation